Company Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates.
The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries.
Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Mar 20, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 181 |
| CEO | John Butler |
Contact Details
Address: 245 First Street, Suite 1400 Cambridge, Massachusetts 02142 United States | |
| Phone | 617 871 2098 |
| Website | akebia.com |
Stock Details
| Ticker Symbol | AKBA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001517022 |
| CUSIP Number | 00972D105 |
| ISIN Number | US00972D1054 |
| Employer ID | 20-8756903 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John P. Butler MBA | Chief Executive Officer, President and Director |
| Erik John Ostrowski M.B.A. | Chief Business Officer, Senior Vice President, Chief Financial Officer and Treasurer |
| Dr. Steven Keith Burke M.D. | Senior Vice President of Research and Development and Chief Medical Officer |
| Nicholas Grund | Senior Vice President and Chief Commercial Officer |
| Richard C. Malabre | Chief Accounting Officer |
| Kimberly Garko | Senior Vice President and Chief Technical Officer |
| Tracey Vetterick | Vice President of Portfolio Strategy and Corporate Administration |
| Mercedes Carrasco | Senior Director of Investor and Corporate Communications |
| Carolyn Rucci | Senior Vice President of Legal, General Counsel and Secretary |
| Meredith Bowman | Senior Vice President and Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 30, 2025 | SCHEDULE 13G | Filing |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 424B5 | Filing |
| Mar 19, 2025 | 424B5 | Filing |